IRIS - Res&Arch Institutional Research Information System - Research & Archive

SPORTOLETTI, PAOLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.907
EU - Europa 2.446
AS - Asia 1.366
SA - Sud America 219
AF - Africa 19
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
Totale 6.963
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.883
IT - Italia 890
SG - Singapore 592
IE - Irlanda 577
HK - Hong Kong 292
RU - Federazione Russa 266
CN - Cina 203
BR - Brasile 199
VN - Vietnam 142
SE - Svezia 124
UA - Ucraina 122
FI - Finlandia 107
DE - Germania 104
RO - Romania 50
KR - Corea 40
GB - Regno Unito 37
AT - Austria 31
BE - Belgio 30
FR - Francia 28
CZ - Repubblica Ceca 18
IN - India 18
TR - Turchia 18
NL - Olanda 17
UZ - Uzbekistan 16
CH - Svizzera 15
CA - Canada 12
LT - Lituania 9
MX - Messico 8
PL - Polonia 7
CI - Costa d'Avorio 6
EC - Ecuador 6
JP - Giappone 5
AR - Argentina 4
BD - Bangladesh 4
IR - Iran 4
PH - Filippine 4
PT - Portogallo 4
SC - Seychelles 4
AZ - Azerbaigian 3
CL - Cile 3
GR - Grecia 3
LB - Libano 3
MA - Marocco 3
NP - Nepal 3
PA - Panama 3
PE - Perù 3
A2 - ???statistics.table.value.countryCode.A2??? 2
DK - Danimarca 2
EU - Europa 2
IL - Israele 2
IM - Isola di Man 2
PK - Pakistan 2
SK - Slovacchia (Repubblica Slovacca) 2
TW - Taiwan 2
ZA - Sudafrica 2
AE - Emirati Arabi Uniti 1
AM - Armenia 1
AO - Angola 1
AU - Australia 1
BN - Brunei Darussalam 1
BO - Bolivia 1
CR - Costa Rica 1
ES - Italia 1
GE - Georgia 1
GH - Ghana 1
ID - Indonesia 1
IQ - Iraq 1
JO - Giordania 1
KE - Kenya 1
KG - Kirghizistan 1
KH - Cambogia 1
KZ - Kazakistan 1
LA - Repubblica Popolare Democratica del Laos 1
NZ - Nuova Zelanda 1
PS - Palestinian Territory 1
PY - Paraguay 1
SA - Arabia Saudita 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 6.963
Salva come PNG Salva come JPEG
Città #
Chandler 594
Dublin 571
Perugia 477
Singapore 411
San Mateo 384
Hong Kong 292
Boardman 206
Santa Clara 151
Dong Ket 140
Altamura 131
Medford 107
Princeton 105
Lawrence 101
Ann Arbor 81
Moscow 71
Wilmington 66
Andover 63
Helsinki 57
Jacksonville 57
Beijing 51
Bucharest 43
Seoul 37
Los Angeles 32
Brussels 30
Rome 28
Des Moines 27
Dearborn 26
Redmond 25
Foligno 23
New York 23
San Paolo di Civitate 20
Ashburn 19
Houston 19
Munich 18
Norwalk 18
Redwood City 17
Vienna 17
Dallas 16
Nuremberg 16
Assisi 15
Izmir 14
Saint Petersburg 14
Shanghai 14
São Paulo 14
Menlo Park 12
Brno 11
Belo Horizonte 9
Woodbridge 9
Chicago 8
Collazzone 8
Falkenstein 8
Falls Church 8
Frankfurt am Main 7
Abidjan 6
Amsterdam 6
Cambridge 6
Guangzhou 6
Milan 6
Nanning 6
Rio de Janeiro 6
Shenzhen 6
Terni 6
Toronto 6
Tower Hamlets 6
Bologna 5
Fairfield 5
Fremont 5
Tashkent 5
Tokyo 5
Vicenza 5
Ancona 4
Bastia 4
Bengaluru 4
Frankfurt Am Main 4
Olomouc 4
Paris 4
Quito 4
San Diego 4
São José dos Campos 4
Tappahannock 4
Alappuzha 3
Baku 3
Brasília 3
Brescia 3
Campobasso 3
Changsha 3
Cotia 3
Council Bluffs 3
Lisbon 3
Maceió 3
Macerata 3
Osimo 3
Ottawa 3
Padova 3
Rohtak 3
The Dalles 3
Zhengzhou 3
Anaheim 2
Auburn Hills 2
Baotou 2
Totale 4.914
Salva come PNG Salva come JPEG
Nome #
Bepridil exhibits anti-leukemic activity associated with NOTCH1 pathway inhibition in chronic lymphocytic leukemia 135
Constitutive phosphorylation of the active Notch1 intracellular domain in chronic lymphocytic leukemia cells with NOTCH1 mutation. 122
Arsenic trioxide and all-trans retinoic acid target NPM1 mutant oncoprotein levels and induce apoptosis in NPM1-mutated AML cells 120
Bcor deficiency perturbs erythro-megakaryopoiesis and cooperates with Dnmt3a loss in acute erythroid leukemia onset in mice 115
Notch1 modulates mesenchymal stem cells mediated regulatory T-cell induction 113
Immune correlates of protection by vaccine against SARS-CoV-2 in patients with chronic lymphocytic leukaemia 107
A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis 102
Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? 102
Activated autologous T cells exert an anti-B-cell chronic lymphatic leukemia effect in vitro and in vivo. 101
Germline NPM1 mutations lead to altered rRNA 2′-O-methylation and cause dyskeratosis congenita 100
Wnt/beta-Catenin Signaling Induces Integrin alpha 4 beta 1 in T Cells and Promotes a Progressive Neuroinflammatory Disease in Mice 98
Mesenchymal cells: a vehicle for gene therapy 96
Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. 92
ARSENIC TRIOXIDE AND ALL-TRANS-RETINOIC ACID TARGET NPM1 MUTANT ONCOPROTEIN LEVELS AND INDUCE APOPTOSIS IN NPM1-MUTATED AML CELLS 92
The radiosensitizer Silver nanoparticles effects are prevent to ion channel blocker DIDS in U251 human glioblastoma cell line. 88
Notch signaling sustains the expression of Mcl-1 and the activity of eIF4E to promote cell survival in CLL 87
NOTCH1 Activation Negatively Impacts on Chronic Lymphocytic Leukemia Outcome and Is Not Correlated to the NOTCH1 and IGHV Mutational Status 85
The NOTCH1/CD39 axis: A Treg trip-switch for GvHD 84
NPM1 AND FLT3-ITD MUTATIONS SINERGISTICALLY INDUCE GATA1 EPIGENETIC SILENCING IN A AML MOUSE MODEL 84
NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications 83
Lack of glucocorticoid-induced leucine zipper (GILZ) deregulates B-cell survival and results in B-cell lymphocytosis in mice 82
NOTCH1 Is Aberrantly Activated in Chronic Lymphocytic Leukemia Hematopoietic Stem Cells. 81
GATA1 epigenetic deregulation contributes to the development of AML with NPM1 and FLT3-ITD cooperating mutations 81
NOTCH1 Aberrations in Chronic Lymphocytic Leukemia. 79
BCOR gene alterations in hematological diseases 78
Clinical-Grade Expanded Regulatory T Cells Prevent Graft-versus-Host Disease While Allowing a Powerful T Cell Dependent Graft-versus-Leukemia Effect in Murine Models 77
Decreased NOTCH1 Activation Correlates with Response to Ibrutinib in Chronic Lymphocytic Leukemia 76
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. 75
Human stromal cells engineered with interleukin-7 enhance the survival of naive T lymphocytes. 74
NOTCH1 inhibition prevents GvHD and maintains GvL effect in murine models 74
BRAF mutations in hairy-cell leukemia. 73
NPM1 AND FLT3-ITD MUTATIONS COOPERATE TO IMPAIR HEMATOPOIETIC STEM/PROGENITOR CELLS DIFFERENTIATION AND DEREGULATE GATA1 IN A MOUSE MODEL OF AML 71
T regulatory cell separation for clinical application. 71
Blockade of Oncogenic NOTCH1 With the SERCA Inhibitor CAD204520 in T Cell Acute Lymphoblastic Leukemia 71
A novel NOTCH1 PEST domain mutation in a case of Chronic Lymphocytic Leukemia 70
Mutant NPM1 Maintains the Leukemic State through HOX Expression 69
Mutational landscape of AML with normal cytogenetics: biological and clinical implications 68
A powerful molecular synergy between mutant Nucleophosmin and Flt3-ITD drives acute myeloid leukemia in mice. 68
Ibrutinib treatment of a patient with relapsing chronic lymphocytic leukemia and sustained remission of Richter syndrome 68
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity 68
Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML 68
IL-4-dependent Jagged1 expression/processing is associated with survival of chronic lymphocytic leukemia cells but not with Notch activation. 67
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 65
A revised NOTCH1 mutation frequency still impacts survival while the allele burden predicts early progression in chronic lymphocytic leukemia 64
NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL. 63
Isolation and characterization of a new human T regulatory cell subset from peripheral blood CD4+ T lymphocyte 63
Richter's transformation in the heart 63
IN VITRO AND IN VIVO ANTILEUKEMIC ACTIVITY OF BEPRIDIL IN CHRONIC LYMPHOCYTIC LEUKEMIA IS ASSOCIATED WITH INHIBITION OF THE NOTCH1 PATHWAY 62
CD4(+) CD25(low) GITR(+) cells: a novel human CD4(+) T-cell population with regulatory activity. 62
Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis. 61
Glucocorticoidi-Induced TNFR family Related gene (GITR) enhances dendritic cell activity 60
The human NPM1 mutation A perturbs megakaryopoiesis in a conditional mouse model. 59
The glucocorticoid-induced TNF receptor family-related protein (GITR) is critical to the development of acute pancreatitis in mice 58
Identification and Characterization of Novel Rare Nucleophosmin (NPM1) Gene Mutations in Acute Myeloid Leukemia (AML) By a Combinatorial Approach of Immunohistochemistry and Molecular Analyses 58
Cytogenetic/mutation profile of chronic lymphocytic leukemia/malignant melanoma collision tumors of the skin 58
Novel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML 58
Interleukin-7-engineered mesenchymal cells: in vitro effects on naive T-cell population. 56
NOTCH and NF-κB interplay in chronic lymphocytic leukemia is independent of genetic lesion. 55
Interleukin 7-engineered stromal cells: a new approach for hastening naive T cell recruitment 54
Mesenchymal cells recruit and regulate T regulatory cells. 54
Mouse models of NPM1-mutated acute myeloid leukemia: biological and clinical implications 53
Venetoclax in CLL patients who progress after B-cell Receptor inhibitor treatment: a retrospective multi-centre Italian experience 53
Loss of bone mineral density and secondary hyperparathyroidism are complications of autologous stem cell transplantation. 53
Up-regulation of translation eukaryotic initiation factor 4E in nucleophosmin 1 haploinsufficient cells results in changes in CCAAT enhancer-binding protein α activity: implications in myelodysplastic syndrome and acute myeloid leukemia. 51
NPM1-mutated acute myeloid leukemia: from bench to bedside 50
Dissecting Clonal Hematopoiesis in Tissues of Classical Hodgkin Lymphoma Patients 50
Case Report: Contrasting BCL2 Upregulation With Venetoclax in a Case of Refractory Lymphomatoid Papulosis and Progressive Chronic Lymphocytic Leukemia 50
Prolonged XPO1 inhibition is essential for optimal antileukemic activity in NPM1-mutated AML 49
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 49
CURCUMIN EXHIBITS IN VITRO AND IN VIVO ANTI-LEUKEMIC ACTIVITY INTERFERING WITH THE NOTCH1 PATHWAY AND INDUCING ENDOPLASMIC RETICULUM STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 48
BEPRIDIL IS A POTENT NOTCH1 INHIBITOR AND EFFICIENTLY INDUCES APOPTOSIS IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) CELLS in vitro AND in vivo 48
Clinical-Grade Expanded Regulatory T Cells Are Enriched with Highly Suppressive Cells Producing IL-10, Granzyme B, and IL-35 48
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 47
Synthesis and characterization of UiO-66 metal-organic frameworks nanoparticles and their evaluation as drug delivery carriers in U251 glioblastoma cells 46
A NOVEL MECHANISM FOR NOTCH1 ACTIVATIONIN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS: INVOLVEMENT OF NOTCH1 ENDOSOMAL TRAFFICKING AND ALTERATIONS IN RAB PROTEINS 46
A scale of "bad" co-mutations in NPM1-driven AML 46
A genetic platform to model sarcomagenesis from primary adult mesenchymal stem cells 45
Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib 45
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation. 44
Lessons, Challenges and Future Therapeutic Opportunities for PI3K Inhibition in CLL 44
Morgana/chp-1, a ROCK inhibitor involved in centrosome duplication and tumorigenesis. 43
A curious novel combination of nucleophosmin (Npm1) gene mutations leading to aberrant cytoplasmic dislocation of npm1 in acute myeloid leukemia (aml) 42
Therapeutic Targeting Potential of Novel Silver Nanoparticles Coated with Anti-CD20 Antibody against Chronic Lymphocytic Leukemia 41
Recurrent primary plasmacytoma of the eyelid with rapid regional metastasis. 41
Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions 41
The cytoplasmic NPM mutant induces myeloproliferation in a transgenic mouse model 40
null 40
NOTCH-1 ACTIVATION AND SUBCLONAL MUTATION NEGATIVELY IMPACT ON CHRONIC LYMPHOCYTIC LEUKEMIA OUTCOMES 39
The landscape of BRAF transcript and protein variants in human cancer. 39
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 38
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 38
null 38
GSK3β is a critical, druggable component of the network regulating the active NOTCH1 protein and cell viability in CLL 37
null 37
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 37
The absent/low expression of CD34 in NPM1-mutated AML is not related to cytoplasmic dislocation of NPM1 mutant protein 36
Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse 36
How does the NPM1 mutant induce leukemia? 36
NOTCH and Graft-Versus-Host Disease 36
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 36
Totale 6.424
Salva come PNG Salva come JPEG
Categoria #
all - tutte 37.683
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 37.683
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020132 0 0 0 0 0 0 0 0 0 107 8 17
2020/2021586 9 23 14 25 165 31 37 29 47 21 35 150
2021/20221.312 48 376 9 44 26 9 18 226 30 138 210 178
2022/20231.946 111 371 18 183 140 195 11 85 708 8 81 35
2023/2024918 40 81 52 35 6 24 282 10 52 31 137 168
2024/20251.812 77 195 63 81 293 142 211 172 478 100 0 0
Totale 7.392